Caption Management’s Haemonetics HAE Stock Holding History

Caption Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-20,300	Closed	-$1.08M	–	1656
2021 Q4	$1.08M	Buy	+20,300	New	+$1.24M	0.01%	1020

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Caption Management's HAE Position: Q1 2022 in Review

Caption Management sold out of Haemonetics (HAE) in Q1 2022, closing a stake of 20,300 shares — an estimated $1.08M sold.

Caption Management first reported a position in HAE in Q4 2021 and held it in 1 quarter. The position peaked at $1.08M in Q4 2021. 242 funds tracked by Wall St. Rank hold HAE as of Q1 2022.

Caption Management reported no remaining Haemonetics position as of Q1 2022 after selling out during the quarter.
Caption Management sold 20,300 Haemonetics shares in Q1 2022, an estimated $1.08M.
Caption Management first reported a position in Haemonetics in Q4 2021 and held it in 1 quarter.
Caption Management's Haemonetics position peaked at $1.08M in Q4 2021.
242 funds tracked by Wall St. Rank held Haemonetics as of Q1 2022.

Based on Caption Management's 13F filing for Q1 2022, filed 13 May 2022.